Drugs / AGA2118
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07361354 | Jan → Sep 2026 overdue | — | Angitia Incorporated Limited | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05225857 | Jun 2022 → Jan 2024 | osteoporosis | Angitia Biopharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06577935 | Oct 2024 → Dec 2026 expected | postmenopausal osteoporosis | Angitia Biopharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGA2118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577935 ↗ |
| Route | Intravenous | “via either SC or IV” NCT05225857 ↗ |
| Route | Subcutaneous | “via either SC or IV” NCT05225857 ↗ |